WCWilliam C. Culp

William C. Culp

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William C. Culp has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Aliza T. Brown

    Department of Radiology, 4301 West Markham Street, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA

    8 shared publications
  • Paula K. Roberson

    Department of Biostatistics, University of Arkansas for Medical Science, 4301 West Markham St., Little Rock, AR 72205

    8 shared publications
  • Rene Flores

    University of Texas School of Nursing at Houston, Houston, TX 77030

    6 shared publications
  • John Lowery

    Laboratory Animal Medicine, 4301 West Markham Street, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA

    5 shared publications
  • Michael J. Borrelli

    Department of Radiology, 4301 West Markham Street, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA

    5 shared publications
  • Robert D. Skinner

    Department of Neurology, University of Arkansas for Medical Science, 4301 West Markham St., Little Rock, AR 72205

    5 shared publications

Latest Publications

  • Stroke transfers for thrombectomy in the era of extended time

    by Sanjeeva Reddy Onteddu, Poornachand Veerapaneni, Krishna Nalleballe, Hisham Elkhider, Sisira Yadala, Karthika Veerapaneni, Deonna Wissler, Sen Sheng, Robert D. Skinner, William C. Culp, et al.


  • Dodecafluoropentane Emulsion in Acute Ischemic Stroke: A Phase Ib/II Randomized and Controlled Dose-Escalation Trial

    by William C. Culp, Sanjeeva S. Onteddu, Aliza Brown, Krishna Nalleballe, Rohan Sharma, Robert D. Skinner, Taylor Witt, Paula K. Roberson, James D. Marsh


  • Dodecafluoropentane Emulsion Extends Window for tPA Therapy in a Rabbit Stroke Model

    by W. C. Culp, A. T. Brown, J. D. Lowery, M. C. Arthur, P. K. Roberson, R. D. Skinner

    Dodecafluoropentane emulsion (DDFPe) nanodroplets are exceptional oxygen transporters and can protect ischemic brain in stroke models 24 h without reperfusion. Current stroke therapy usually fails to reach patients because of delays following stroke onset. We tested using DDFPe to extend the time window for tissue plasminogen activator (tPA). Longer treatment windows will allow more patients more complete stroke recovery. We test DDFPe to safely extend the time window for tPA thrombolysis to 9 h after stroke. With IACUC approval, randomized New Zealand white rabbits (3.4–4.7 kg, n = 30) received angiography and 4-mm blood clot in the internal carotid artery for flow-directed middle cerebral artery occlusion. Seven failed and were discarded. Groups were IV tPA (n = 11), DDFPe + tPA (n = 7), and no therapy controls (n = 5). DDFPe (0.3 ml/kg, 2 % emulsion) IV dosing began at 1 h and continued at 90 min intervals for 6 doses in one test group; the other received saline injections. Both got standard IV tPA (0.9 mg/kg) therapy starting 9 h post stroke. At 24 h, neurological assessment scores (NAS, 0–18) were determined. Following brain removal percent stroke volume (%SV) was measured. Outcomes were compared with Kruskal-Wallis analysis. For NAS, DDFPe + tPA was improved overall, p = 0.0015, and vs. tPA alone, p = 0.0052. For %SV, DDFPe + tPA was improved overall, p = 0.0003 and vs. tPA alone, p = 0.0018. NAS controls and tPA alone were not different but %SV was, p = 0.0078. With delayed reperfusion, DDFPe + tPA was more effective than tPA alone in preserving functioning brain after stroke. DDFPe significantly extends the time window for tPA therapy.


  • Open Access

    Dodecafluoropentane Emulsion (DDFPe) Decreases Stroke Size and Improves Neurological Scores in a Permanent Occlusion Rat Stroke Model

    by A.T Brown, M.C Arthur, J.S Nix, J.A Montgomery, R.D Skinner, P.K Roberson, Michael Borrelli, W.C Culp

    Background: Dodecafluoropentane emulsion (DDFPe), given IV one hour after stroke, has been shown to greatly reduce the percent stroke volume (%SV) in rabbits. With repeated doses its effect continued for 24 hours. Purpose: Test DDFPe as neuroprotective agent in permanent occlusion rat stroke models in Sprague Dawley (SD) and Spontaneously Hypertensive Rats (SHR) measuring both %SV and neurological assessment scores (NAS). Methods: The male rats received either saline (control), or one or four doses (1x or 4x) of DDFPe (0.6ml/kg IV) one hour post stroke. Treatment groups were SD (n=26) (control, 1x and 4x; n=12, 7 and 7) and SHR (n=14) (control, 1x and 4x; n=7, 3 and 4). The 4x doses were given at 1.5 hour intervals. At six hours post stroke, the rats received a NAS using standard tests for balance, reflexes, and motor performance. Then rats were euthanized and brains removed for TTC evaluation of %SV. Results: For %SV analysis strain differences were not significant therefore strains were combined. DDFPe significantly decreased %SV in 1x and 4xDDFPe groups compared to control groups (2.59±1.81 and 0.98±0.88 vs. 9.24±6.06, p≤0.001 each; p≤0.0001 for the overall test for treatment effect). The 1x versus 4xDDFPe groups were not significantly different (p=0.40). In NAS analysis both strains showed significant improvement with 4xDDFPe therapy vs. controls, (SD: 5.00+2.45 vs. 9.36+3.56, p=0.01; SHR: 7.75+4.43 vs. 12.14+3.08, p=0.05). Differences between the 1x DDFPe group and controls were not significant (SD: 8.43+3.69; SHR: 9. 33+3.51). Conclusion: DDFPe treatment provides significant neuroprotection when assessed six hours post stroke.


  • Open Access

    Neurological Assessment Scores in Rabbit Embolic Stroke Models

    by Aliza Brown, Sean Woods, Robert Skinner, Jeff Hatton, John Lowery, Paula Roberson, Leah Hennings, William C Culp

    Background: Neurological outcomes and behavioral assessments are widely used in animal models of stroke, but assessments in rabbit models are not fully validated. The wryneck model of neurological assessment scores (NAS) was compared to percent infarct volume (%IV) values (infarct volume is a proven clinical indicator of stroke severity) and arterial occlusion localization in three rabbit angiographic stroke models. Hypothesis: NAS values will correlate with percent infarct volume values. Methods: Anesthetized New Zealand White rabbits (N=131, 4-5 kg) received internal carotid artery emboli by angiographic catheter introduced into the femoral artery and occlusions were characterized. Rabbits were evaluated at 24 hours post embolism using the NAS test of 0 (normal) to 10 (death). Deficit criteria included neck twist, righting reflex, extension reflex in hind paw and forepaw, and posture. Brain sections stained with triphenyltetrazolium chloride (TTC) were analyzed for %IV. Volume of the infarct was measured and calculated as a percent of the total brain volume. Results: The aggregate correlation for NAS values vs. %IV values was R=0.61, p<0.0001, a strong positive relationship, while correlations of the NAS components ranged from R=0.28-0.46. Occlusionsof the posterior cerebral artery vs. the middle cerebral artery alone produced significantly greater deficit scores at p<0.0001. Conclusions: These positive results validate the NAS system in the rabbit angiographic embolic stroke model.


  • Progress in Dodecafluoropentane Emulsion as a Neuroprotective Agent in a Rabbit Stroke Model

    by S. D. Woods, R. D. Skinner, A. M. Ricca, A. T. Brown, J. D. Lowery, M. J. Borrelli, J. O. Lay, W. C. Culp

    Dodecafluoropentane emulsion (DDFPe) in 250 nm nanodroplets seems to swell modestly to accept and carry large amounts of oxygen in the body at >29 °C. Small particle size allows oxygen delivery even into hypoxic tissue unreachable by erythrocytes. Using permanent cerebral embolic occlusion in rabbits, we assessed DDFPe dose response as a neuroprotectant at 7 and 24 h post-embolization without lysis of arterial obstructions and investigated blood pharmacokinetics. New Zealand White rabbits (N = 56) received cerebral angiography and embolic spheres (diameter = 700–900 μm) occluded middle and/or anterior cerebral arteries. Intravenous DDFPe dosing (2 % w/v emulsion) began at 60 min and repeated every 90 min until sacrifice at 7 or 24 h post-embolization. Seven-hour groups: (1) control (embolized without treatment, N = 6), and DDFPe treatment: (2) 0.1 ml/kg (N = 7), (3) 0.3 ml/kg (N = 9), (4) 0.6 ml/kg (N = 8). Twenty-four-hour groups: (5) control (N = 16), and DDFPe treatment: (6) 0.1 ml/kg (N = 10). Infarcts as percent of total brain volume were determined using vital stains on brain sections. Other alert normal rabbits (N = 8) received IV doses followed by rapid arterial blood sampling and GC-MS analysis. Percent infarct volume means significantly decreased for all DDFPe-treated groups compared with controls, p = <0.004 to 90 min, suggests multiple compartments. Lowest effective dose and maximum effective therapy duration are not yet defined. Rapid development is warranted.


  • Three variations in rabbit angiographic stroke models

    by William C. Culp, Sean D. Woods, Aliza T. Brown, John D. Lowery, Leah J. Hennings, Robert D. Skinner, Michael J. Borrelli, Paula K. Roberson


  • Dodecafluoropentane Emulsion Decreases Infarct Volume in a Rabbit Ischemic Stroke Model

    by William C. Culp, Sean D. Woods, Robert D. Skinner, Aliza T. Brown, John D. Lowery, Jennifer L.H. Johnson, Evan C. Unger, Leah J. Hennings, Michael J. Borrelli, Paula K. Roberson


  • Successful Microbubble Sonothrombolysis Without Tissue-Type Plasminogen Activator in a Rabbit Model of Acute Ischemic Stroke

    by William C. Culp, Rene Flores, Aliza T. Brown, John D. Lowery, Paula K. Roberson, Leah J. Hennings, Sean D. Woods, Jeff H. Hatton, Benjamin C. Culp, Robert D. Skinner, et al.

    Background and Purpose—: Microbubbles (MB) combined with ultrasound (US) have been shown to lyse clots without tissue-type plasminogen activator (tPA) both in vitro and in vivo. We evaluated sonothrombolysis with 3 types of MB using a rabbit embolic stroke model. Methods—: New Zealand White rabbits (n=74) received internal carotid angiographic embolization of single 3-day-old cylindrical clots (0.6×4.0 mm). Groups included: (1) control (n=11) embolized without treatment; (2) tPA (n=20); (3) tPA+US (n=10); (4) perflutren lipid MB+US (n=16); (5) albumin 3 μm MB+US (n=8); and (6) tagged albumin 3 μm MB+US (n=9). Treatment began 1 hour postembolization. Ultrasound was pulsed-wave (1 MHz; 0.8 W/cm 2 ) for 1 hour; rabbits with tPA received intravenous tPA (0.9 mg/kg) over 1 hour. Lipid MB dose was intravenous (0.16 mg/kg) over 30 minutes. Dosage of 3 μm MB was 5×10 9 MB intravenously alone or tagged with eptifibatide and fibrin antibody over 30 minutes. Rabbits were euthanized at 24 hours. Infarct volume was determined using vital stains on brain sections. Hemorrhage was evaluated on hematoxylin and eosin sections. Results—: Infarct volume percent was lower for rabbits treated with lipid MB+US (1.0%±0.6%; P =0.013), 3 μm MB+US (0.7%±0.9%; P =0.018), and tagged 3 μm MB+US (0.8%±0.8%; P =0.019) compared with controls (3.5%±0.8%). The 3 MB types collectively had lower infarct volumes ( P =0.0043) than controls. Infarct volume averaged 2.2%±0.6% and 1.7%±0.8% for rabbits treated with tPA alone and tPA+US, respectively ( P =nonsignificant). Conclusions—: Sonothrombolysis without tPA using these MB is effective in decreasing infarct volumes. Study of human application and further MB technique development are justified.


  • Variations in the Circle of Willis in the New Zealand White Rabbit

    by Brian Caldwell, Rene Flores, John Lowery, Aliza T. Brown, William C. Culp